Various clinical trials studying colchicine or IL‐1 inhibition in stable or acutely decompensated HF with reduced ejection fraction (reviewed in Olsen et al. 136)have also failed to convincingly demonstrate a strong protective potential. This evidence concerns the gene IL1A and hydrops fetalis.